Drug Profile
Research programme: astaxanthin prodrugs - Cardax Pharmaceuticals
Alternative Names: CDX-085; Heptax; XanCorLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Cardax Pharmaceuticals
- Class Anti-inflammatories; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antirheumatics; Antithrombotics; Hepatoprotectants; Nootropics; Vascular disorder therapies; Xanthophylls
- Mechanism of Action Antioxidants; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
- No development reported Atherosclerosis; Cognition disorders; Dyslipidaemias; Hypertriglyceridaemia; Inflammation; Liver disorders; Metabolic syndrome; Osteoarthritis; Rheumatoid arthritis; Thrombosis; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for research development in Dyslipidaemias in USA (PO)
- 28 Jun 2023 No recent reports of development identified for research development in Inflammation in USA (PO)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Osteoarthritis in USA (PO)